Dudediligence.

Iovance Biotherapeutics, Inc

IOVANASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$58.6MSep ’24$73.7MDec ’24$49.3MMar ’25$60.0MJun ’25$67.5MSep ’25$86.8MDec ’25$71.4MMar ’26$99.3MJun ’26
Net income, by quarter
−$83.5MSep ’24−$78.6MDec ’24−$116.2MMar ’25−$111.7MJun ’25−$91.3MSep ’25−$71.9MDec ’25−$79.0MMar ’26−$47.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on filenone on file$1.2M$164.1M$263.5M
Gross profitnone on filenone on file$156,000$70.8M$90.3M
Operating income−$342.7M−$398.9M−$460.6M−$395.3M−$403.4M
Net income−$342.3M−$395.9M−$444.0M−$372.2M−$391.0M
Operating cash flow−$227.9M−$292.8M−$361.8M−$353.0M−$302.4M
Free cash flow−$265.5M−$313.2M−$384.1M−$364.0M−$336.2M
Cash$78.2M$231.7M$114.9M$115.7M$163.1M
Shares outstanding157.0M187.8M256.1M305.3M411.9M